Leuprolide Acetate Market Report 2026

The leuprolide acetate market size has grown strongly in recent years. It will grow from $2.71 billion in 2025 to $2.9 billion in 2026 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to prostate cancer prevalence, endometriosis management needs, hospital-based hormone therapy, injectable drug adoption, established GnRH agonist efficacy.

The leuprolide acetate market size is expected to see strong growth in the next few years. It will grow to $3.71 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging male population, increasing uterine fibroid diagnosis, long-acting formulation demand, outpatient hormone therapy growth, fertility treatment expansion. Major trends in the forecast period include rising use in hormone-dependent disorders, expansion of long-acting depot formulations, growth of oncology and gynecology applications, increased preference for injectable hormonal therapies, product innovation in controlled release systems.

The increasing prevalence of prostate cancer is expected to drive growth in the leuprolide acetate market in the coming years. Prostate cancer is a malignancy that develops in the glandular cells of the prostate, a male-specific organ located below the bladder, and is among the most common cancers in men worldwide. The rising incidence of prostate cancer is largely driven by an aging population, as the risk of developing the disease increases significantly with age. Leuprolide acetate aids in prostate cancer treatment by reducing testosterone levels, slowing tumor growth, and managing advanced disease, thereby improving patient outcomes. For example, according to the Centers for Disease Control and Prevention in January 2025, 255,395 new cases of prostate cancer were reported in the United States in 2022, and 33,881 men died from the disease in 2023. Therefore, the increasing prevalence of prostate cancer is driving growth in the leuprolide acetate market.

Key companies in the leuprolide acetate market are focusing on innovative solutions, such as generic injectable formulations, to enhance accessibility and reduce treatment costs. Generic injectable formulations are non-branded versions of injectable drugs with the same active ingredients and dosage as the original, providing more affordable and widely available treatment options. For instance, in June 2025, Avenacy, a US-based specialty pharmaceutical company, launched Leuprolide Acetate Injection, a generic equivalent provided in a 14-day patient-administration kit. The kit includes a 14 mg / 2.8 mL multi-dose vial (1 mg per 0.2 mL), 14 disposable syringes, and 28 alcohol wipes, allowing patients to self-administer doses safely over two weeks. Designed to reduce clinic visits, the kit also offers cost savings, convenience, and packaging optimized for accurate medication selection, making it suitable for retail and mail-order pharmacy distribution.

In December 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, entered into an exclusive licensing agreement with Daewoong Pharmaceutical Co. Ltd. to co-develop and commercialize leuprolide acetate for depot suspension. This collaboration leverages Daewoong’s proprietary technology and formulation expertise along with Zydus’s market presence to bring an advanced, long-acting hormonal therapy to global markets. Daewoong Pharmaceutical Co. Ltd., based in South Korea, specializes in innovative drug delivery and provides leuprolide acetate for hormone-related treatments.

Major companies operating in the leuprolide acetate market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Apotex Inc., Aurobindo Pharma Limited, Lupin Limited, Baxter International Inc., Accord Healthcare Ltd., Glenmark Pharmaceuticals Limited, Strides Pharma Science Limited, Amring Pharmaceuticals Inc., MSN Laboratories Pvt Ltd., Wockhardt Limited, Bharat Parenterals Limited, Reliance Life Sciences Pvt Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Harbin Pharmaceutical Group Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Qilu Pharmaceutical Co. Ltd., Kelun Pharmaceutical Co. Ltd., Chengdu Tiantaishan Pharmaceutical Co. Ltd., Beijing SL Pharmaceutical Co. Ltd.

North America was the largest region in the leuprolide acetate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leuprolide acetate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the leuprolide acetate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the leuprolide acetate market by increasing costs for hormone-grade active pharmaceutical ingredients, lyophilization materials, injectable packaging, and prefilled syringe components. Oncology and reproductive health applications such as prostate cancer, endometriosis, and precocious puberty are most affected, especially in North America and Europe due to global sourcing of drug substances and delivery devices. Hospitals and clinics face rising procurement costs. On the positive side, tariffs are driving investment in local sterile injectable manufacturing and formulation capacity.

The leuprolide acetate market research report is one of a series of new reports that provides leuprolide acetate market statistics, including leuprolide acetate industry global market size, regional shares, competitors with a leuprolide acetate market share, detailed leuprolide acetate market segments, market trends and opportunities, and any further data you may need to thrive in the leuprolide acetate industry. This leuprolide acetate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist primarily used to suppress hormone production. It lowers estrogen and testosterone levels by initially stimulating and then inhibiting the pituitary gland. It is mainly used to treat hormone-sensitive conditions such as prostate cancer, endometriosis, uterine fibroids, and precocious puberty.

The main product types of leuprolide acetate include vials, prefilled syringes, and lyophilized powder. Vials are small glass or plastic containers used to store the drug in liquid form for injection. Administration routes include intramuscular, subcutaneous, intranasal, and implantation methods. The drug is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Its applications include prostate cancer, endometriosis, uterine fibroids, central precocious puberty, infertility, hormone therapy, and others, serving end users such as hospitals, clinics, homecare settings, and research laboratories.

The leuprolide acetate market consists of sales of long-acting depot injections and custom compounded forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.